CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 6,911	$ 5,421
Marketable securities, current	1,973	1,391
Receivables	5,965	6,300
Inventories	1,195	1,166
Prepaid expenses and other	1,116	576
Total Current Assets	17,160	14,854
Property, plant and equipment	5,027	5,001
Goodwill	6,538	6,863
Other intangible assets	1,091	1,210
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent	1,371	1,610
Marketable securities, noncurrent	1,775	2,480
Other Assets, Noncurrent	2,024	1,533
Total Assets	34,986	33,551
Current Liabilities:
Short-term debt obligations	1,703	987
Accounts payable	1,892	2,248
Accrued liabilities	6,489	6,014
Deferred income, current	172	83
Income taxes payable, current	398	231
Total Current Liabilities	10,654	9,563
Deferred income, noncurrent	468	454
Income taxes payable, noncurrent	3,043	3,548
Pension and other liabilities	1,048	1,164
Long-term debt, excluding current maturities	5,646	6,975
Total Liabilities	20,859	21,704
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,070 in 2017 and 4,129 in 2016, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2017 and 2016	221	221
Capital in excess of par value of stock	2,081	1,898
Accumulated other comprehensive loss	(2,762)	(2,289)
Retained earnings	34,065	31,160
Less cost of treasury stock - 575 million common shares in 2017 and 536 million in 2016	(19,574)	(19,249)
Total Bristol-Myers Squibb Company Shareholders' Equity	14,031	11,741
Noncontrolling interest	96	106
Total Equity	14,127	11,847
Total Liabilities and Equity	$ 34,986	$ 33,551